Schneider Worldwide

After apparently exhausting every other means of obtaining access to the drug it needs to enter the drug-eluting stent (DES) market as quickly as possible, Guidant Corp. 's decision to acquire Coo

Can this family-run company continue providing superior technology and responsiveness in the transition from OEM supplier to full-fledged interventional vascular products company? by Stephen Levin And

Seven years and $175 million later, Novoste is ready to test the market for radiation therapy to treat restenosis. by David Cassak In the last weeks of 1999, as the date for this year's American Colle

When Jim Tobin arrived at Boston Scientific Corp. as its new CEO, the company was under a storm of criticism for sloppy operations and some embarrassing mis-steps. Tobin was brought in to fix the p